{"id":"carboplatin-5fu-concomitant","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Mucositis"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"50-70","effect":"Anemia"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing cell replication and triggering apoptosis. 5FU is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and also affecting RNA function. The combination is used concomitantly to enhance cytotoxic effects against cancer cells, particularly in head and neck malignancies.","oneSentence":"Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:56.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck cancer (squamous cell carcinoma)"},{"name":"Locally advanced or metastatic head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT02778191","phase":"","title":"Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2016-02","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":413},{"nctId":"NCT06062602","phase":"EARLY_PHASE1","title":"PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2021-07-26","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT00006472","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2000-01","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT00609284","phase":"PHASE3","title":"Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2008-02-15","conditions":"HNSCC","enrollment":406},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00158652","phase":"PHASE3","title":"Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2000-03","conditions":"Oral Cancer, Oropharynx Cancer, Hypopharynx Cancer","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carboplatin, 5FU concomitant","genericName":"Carboplatin, 5FU concomitant","companyName":"Groupe Oncologie Radiotherapie Tete et Cou","companyId":"groupe-oncologie-radiotherapie-tete-et-cou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells. Used for Head and neck cancer (squamous cell carcinoma), Locally advanced or metastatic head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}